misitatug blivedotin (RC88) / Rongchang Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
misitatug blivedotin (RC88) / Rongchang Pharma
RC88-C008, CTR20233195: A multicenter, single-arm phase II clinical study to evaluate the efficacy, safety, and pharmacokinetics of RC88 in platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary membrane cancer

Not yet recruiting
2
88
China
RC88 - Rongchang Pharma
Remegen Biopharmaceutical (Yantai) Co., Ltd./ Remegen Biopharmaceutical (Yantai) Co., Ltd
Platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer
 
 
NCT06173037: RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Recruiting
2
88
RoW
RC88, RC88 for Injection
RemeGen Co., Ltd.
Primary Peritoneal Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer
06/26
12/26
NCT04175847: A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors

Recruiting
1/2
200
RoW
RC88, RC88 for Injection
RemeGen Co., Ltd.
Solid Tumor
09/24
09/25
NCT05804526: A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours

Recruiting
1/2
82
RoW
RC88, Sintilimab Injection, Sintilimab
RemeGen Co., Ltd.
Advanced Solid Tumours
05/25
12/25
NCT05508334: A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours

Recruiting
1
81
RoW
RC88, The injectable RC88
RemeGen Co., Ltd.
Advanced Solid Tumours
06/24
12/24

Download Options